THE WOODLANDS, Texas, July 13, 2004 (PRIMEZONE) -- Power3 Medical Products, Inc. (OTCBB:PWRM) announces today the completion of a stage of clinical validation on its neurodegenerative disease blood test, developed by the Company in collaboration with Stan Appel, M.D., Chairman of the Department of Neurology at Baylor College of Medicine and one of the most recognized leaders in neuromuscular and neurodegenerative disease. The completed study, which involved analyzing additional serum samples from 104 patients with Lou Gehrig's (ALS), Parkinson's, Alzheimer's, and other neurological diseases, concurs with the Company's previous positive results, obtained with 79 patients and healthy individuals as a proof of concept.
During this phase of the collaboration between the research team of Power3 Medical under Dr. Ira L. Goldknopf, Chief Scientific Officer, and the team at Baylor, 183 neurodegenerative disease patients' and normal individuals' samples were analyzed, using the Company's patent-pending proteomic methods, to develop the ability to selectively diagnose in the blood serum, the neurodegenerative diseases. The test was able to discriminate between normal individuals and patients with neurodegenerative diseases at a level of 86-99%. Furthermore, when evaluated on a mixed pool of blinded sera from the patients, the preliminary results indicated an accurate differential diagnosis of ALS, Alzheimer's and Parkinson's diseases, at a level of 60-70%.
According to Dr. Ira Goldknopf, "With this test, which involves monitoring the concentration of a panel of proteins in the blood, we are able to identify unique biomarkers whose profiles appear to distinguish patients with Lou Gehrig's (ALS), Alzheimer's, and Parkinson's diseases from each other as well as from the normal individuals and patients with other neurological disorders. To our gratification, this test has exceeded our expectations and these results propel us to continue clinical validation."
Dr. Stan Appel, commented, "These protein biomarkers identified by Power3 represent a promise for early detection and identification of ALS, Alzheimer's, Parkinson's and other neurological diseases. A main problem to date is that there are no diagnostic tests or biomarkers for the early diagnosis, prognosis, and guidelines for therapy for neurodegenerative diseases. We are pleased with the progress that has been made. These biomarkers have the potential to offer unique insights into the pathogenesis of neurodegenerative disease and provide great promise to improve the clinical outcomes of our patients."
About Power3 Medical Products, Inc.
Power3 Medical Products, www.Power3Medical.com, is a leading edge biotechnology company engaged in the discovery of protein footprints, pathways, and mechanisms of diseases that the Company's proprietary technology can detect in patients. These discoveries are being used to develop screening and diagnostic tests for the early detection and treatment of disease. The protein biomarkers, drug targets, and diagnostic tests are targeted toward markets with critical unmet needs in areas such as breast cancer and neurodegenerative disease. The Company is in a strong competitive position with over 250 identified biomarkers of human disease and operates a state-of-the-art proteomics laboratory in The Woodlands, Texas.
In addition, all current shareholders, and interested parties should sign into our private Corporate Guest Book, www.CorporateGuestBook.com/?PWRM to receive timely updates and information on future developments.
Safe Harbor Statement
All statements other than statements of historical fact included in this press release are "forward-looking statements." The forward-looking statements, including statements about the Company's future expectations, including future revenues and earnings, and all other forward-looking statements (i.e., future operational results and sales) are subject to assumptions and beliefs based on current information known to the Company and factors that are subject to uncertainties, risk and other influences, which are outside the Company's control, and may yield results differing materially from those anticipated.